How to Develop ALK Degraders: Degrader Types and Structural Design

* Please be kindly noted that our services and products are intended for research use by organizations or companies and are not intended for individual use.

Consult with Our Experts

What Is ALK, and Which ALK Forms Are Suitable for Degrader Development?

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor superfamily and is encoded by the ALK gene on chromosome 2p23. The full-length human ALK protein contains approximately 1,620 amino acids and consists of an extracellular domain (ECD), a single-pass transmembrane domain, and an intracellular domain (ICD). Its intracellular region contains a tyrosine kinase domain responsible for ATP-dependent phosphorylation and downstream signaling. Under normal conditions, ALK participates in nervous system development and cellular signaling. However, chromosomal rearrangements, activating mutations, and abnormal protein expression can produce oncogenic ALK forms with sustained kinase activity.

The extracellular domain of full-length ALK has a distinctive architecture containing two meprin/A5 protein/PTPmu (MAM) domains, a low-density lipoprotein receptor class A (LDLa) domain, and a glycine-rich region. The transmembrane segment connects this extracellular region to the intracellular kinase domain. This structural organization provides two fundamentally different opportunities for degrader development: intracellular recognition of the kinase domain and extracellular recognition of the intact receptor. Most established ALK PROTACs exploit the former because the kinase domain contains a well-characterized ATP-binding pocket with multiple small-molecule ligands.

ALK fusion proteins represent another important target category. EML4::ALK is generated through a rearrangement involving echinoderm microtubule-associated protein-like 4 (EML4), while NPM::ALK contains the nucleophosmin (NPM1) fusion partner. These fusion proteins generally retain the ALK intracellular kinase domain but lose the extracellular and transmembrane regions of the full-length receptor. Their fusion partners contribute oligomerization or localization properties that promote abnormal ALK activation. Consequently, kinase-domain-directed degraders can recognize the shared ALK portion without requiring a ligand that specifically binds the fusion junction.

ALK point mutations create additional target forms with distinct structural and degradation requirements. In neuroblastoma-associated ALK, important activating mutations include F1174L, R1275Q, and F1245C. In ALK fusion proteins, acquired kinase-domain mutations include L1196M, G1202R, C1156Y, I1171T/N, V1180L, G1269A, and D1203N. Among these, L1196M is a gatekeeper mutation, whereas G1202R is a solvent-front mutation. Compound mutations, particularly G1202R/L1196M, can produce substantial changes in inhibitor recognition and represent an important design challenge for ALK degraders.

Therefore, ALK degrader development should begin by identifying the precise protein form rather than treating all ALK-positive models as equivalent. Full-length ALK, fusion-derived ALK, activating point mutants, and acquired resistance mutants may retain different structural regions, intracellular distributions, and accessible recognition surfaces.

Table 1. ALK Structural Regions and Their Implications for Degrader Development.

Developed ALK Degraders and Their Research Progress

ALK degrader research has progressed from early inhibitor-derived PROTACs to mutation-resilient degraders, miniaturized PROTACs, hydrophobic tags, and molecular glue approaches. The initial studies established that ALK fusion proteins could be depleted by connecting kinase inhibitors to E3 ligase ligands. Subsequent research demonstrated that degradation efficiency depends on more than the affinity of the ALK-binding ligand. The selected linker, E3 recruitment geometry, intracellular exposure, and structural context of the target all influence the final degradation profile.

Early examples include TD-004, which combines a ceritinib-derived ALK-binding component with a VHL recruiter, and MS4078, which connects a ceritinib-based ligand to a cereblon (CRBN) recruiter. Later studies introduced TAE684-, alectinib-, and brigatinib-derived structures. These studies established CRBN and VHL as important E3 recruitment systems and demonstrated that different linker architectures can produce substantially different ALK degradation profiles.

More recent studies have expanded the design space. CPD-1224 demonstrated catalytic degradation of resistant EML4::ALK forms, including the G1202R/L1196M compound mutant. WZH-17-002, constructed using the mutation-tolerant ALK inhibitor WZH-15-125, further demonstrated activity against lorlatinib-resistant compound mutations. In parallel, AP-1 introduced an ultrashort-linker architecture, while gilteritinib-based PROTACs demonstrated that E3 recruiter selection and linker length can determine whether EML4::ALK and NPM::ALK are effectively degraded.

Nonclassical degradation strategies have also produced direct ALK research examples. Norbornene- and adamantane-based hydrophobic tags promote ALK degradation through chaperone-associated mechanisms. Linker-free amino-acid degrons provide another approach by connecting an ALK-binding ligand directly to a degradation signal. In 2026, TRI-611 further demonstrated an orthogonal strategy: a molecular glue that promotes ALK kinase-domain and CRBN proximity through a recognition interface outside the conventional ATP-binding site.

Table 2. Representative Developed ALK Degraders and Their Research Findings.

These studies provide several important design lessons. First, CRBN has the broadest range of reported ALK degrader precedents, but it is not universally optimal. VHL-based designs can be productive in suitable structural contexts, while IAP-based designs have demonstrated fusion-dependent activity. Second, linker optimization should be treated as a central structural task rather than a simple distance adjustment. Third, resistance coverage must be demonstrated at the protein-degradation level because improved inhibition of a mutant does not automatically establish efficient degradation. Finally, hydrophobic tagging, linker-free degrons, and molecular glue approaches provide alternatives when conventional bifunctional PROTAC architectures encounter structural or developability limitations.

ATP-Competitive ALK PROTAC Design for Kinase-Domain Targeting

Target Site: ALK Kinase Domain ATP Pocket, Hinge Region, and Solvent-Exposed Exit Vectors

The ALK intracellular kinase domain is the most established starting point for conventional PROTAC development. Its ATP-binding pocket is formed by the N-lobe and C-lobe of the kinase domain, with the hinge region providing important hydrogen-bonding interactions for ATP-competitive inhibitors. The gatekeeper residue L1196, solvent-front residue G1202, αC-helix region, and activation loop contribute to the local structural environment and influence inhibitor recognition. A suitable degrader warhead must preserve the interactions required for ALK binding while providing a solvent-accessible position for linker attachment.

Structural analysis should distinguish the buried ATP-binding interactions from peripheral substituents that extend toward the surrounding solvent. The hinge-binding region generally contributes to ligand anchoring, whereas substituents projecting outside the pocket may provide more practical conjugation positions. For example, structural analysis of the ALK-brigatinib complex identified its solvent-exposed piperidine region as a suitable attachment point for PROTAC linker installation. This strategy was used in the development of brigatinib-derived degraders.

The ATP pocket should not be treated as a completely rigid structure. Different ALK conformations, inhibitor-binding modes, and resistance mutations can change the accessibility of peripheral substituents. Therefore, structural evaluation should consider the target-bound ligand pose, the direction of the potential linker exit vector, and the position of the recruited E3 ligase relative to the kinase surface.

Warhead Selection: Crizotinib-, Ceritinib-, Alectinib-, Brigatinib-, and Lorlatinib-Type Scaffolds

Inhibitor-derived ALK ligands provide the most direct starting point for conventional ALK PROTAC development. However, different inhibitor scaffolds should be prioritized according to their binding mode, available attachment positions, and ability to retain target engagement after conjugation.

• Ceritinib-derived scaffolds: provide an established starting point for ALK degradation. TD-004, MS4078, and CPD-1224 demonstrate that ceritinib-related recognition elements can be incorporated into different CRBN- or VHL-associated degrader architectures. The attachment position should preserve the key kinase-pocket interactions while allowing the E3 recruiter to extend into solvent.
• Alectinib-derived scaffolds: provide an alternative kinase-binding framework. SIAIS001 and SIAIS091 demonstrate the feasibility of combining alectinib-derived ligands with lenalidomide- or thalidomide-based CRBN recruiters. The selected attachment position should retain the parent ligand's binding profile after structural modification.
• Brigatinib-derived scaffolds: have particularly useful structural precedents. SIAIS117 and SIAIS164018 demonstrate VHL- and CRBN-associated designs, respectively. The solvent-exposed piperidine region provides a practical starting point for linker installation.
• TAE684-derived scaffolds: provide another kinase-binding option, represented by the TL13 degrader series. These structures support comparative evaluation of ALK ligand chemotypes rather than dependence on one inhibitor scaffold.
• Crizotinib- and lorlatinib-type scaffolds: may be considered as exploratory ligand sources when structural and binding evidence supports their use. However, a crizotinib-derived PROTAC developed for another kinase should not be interpreted as an established ALK degrader, and lorlatinib-resistant degrader examples do not necessarily use lorlatinib itself as the warhead.
• Alternative kinase-binding scaffolds: gilteritinib-based PROTAC research demonstrates that an inhibitor originally developed around another kinase can also provide an ALK-binding element when its ALK recognition profile is experimentally confirmed.

Linker Design: Attachment Point, Length, Rigidity, and Polarity

Linker design determines whether the ALK-bound warhead can position the recruited E3 ligase in a productive orientation. The first decision should be the attachment point on the inhibitor scaffold. A linker attached too close to the hinge-binding region or a buried pocket substituent may disrupt ALK recognition. A solvent-exposed substituent is generally preferable because it provides a more direct route for extending the molecular structure outside the kinase pocket.

Published ALK degrader studies demonstrate that neither the shortest nor the longest linker is universally optimal. In brigatinib-derived SIAIS117 development, a series of alkyl linkers was evaluated, with a longer C9 architecture providing an effective design. In contrast, the 2024 gilteritinib-based study found that shorter PEG-containing linkers generally supported better ALK degradation than longer analogues. SIAIS164018 also demonstrated that a short acetyl linker could support productive CRBN recruitment when combined with an appropriate ALK-binding scaffold.

AP-1 further demonstrated the value of minimizing linker length. Its two-atom linker reduced the overall molecular size while maintaining effective target and E3 engagement. More recently, polyhedral alkane linkers, including cubane, homocubane, adamantane, D₃-trihomocubane, and norbornene, have been explored in brigatinib- and lenalidomide-based ALK PROTACs. These rigid three-dimensional structures offer an alternative to conventional linear alkyl and PEG linkers.

• Attachment position: prioritize solvent-exposed substituents and verify that conjugation does not disrupt the hinge-binding geometry.
• Length optimization: compare short, intermediate, and extended linkers using matched warhead and E3 recruiter combinations.
• Rigidity: evaluate flexible PEG or alkyl chains alongside piperidine, piperazine, heterocyclic, and polyhedral structures.
• Polarity: balance hydrophilic segments and hydrophobic regions to maintain solubility without compromising cellular uptake.
• Geometry: assess the complete ALK-PROTAC-E3 ternary complex rather than optimizing the distance between the two ligands independently.

E3 Ligase Selection: CRBN, VHL, IAP, and MDM2 Recruitment for ALK Degradation

CRBN and VHL are the two most established E3 recruitment systems in inhibitor-derived ALK PROTAC research. CRBN has been used in MS4078, the alectinib-derived SIAIS series, SIAIS164018, CPD-1224, and WZH-17-002. Pomalidomide- and lenalidomide-derived ligands provide practical starting points, while their attachment positions and linker orientations must be evaluated in the complete molecular architecture.

VHL recruitment is supported by TD-004 and SIAIS117. These examples demonstrate that a VHL-based architecture can efficiently degrade ALK when the selected target ligand and linker provide a compatible ternary complex. However, the 2024 gilteritinib-based comparison showed that its VHL-recruiting designs did not effectively degrade the tested ALK fusion proteins, whereas CRBN-based designs were productive. This difference emphasizes that E3 selection is dependent on the complete target-warhead-linker system.

IAP recruitment has also been investigated directly. In the gilteritinib-based series, an IAP-recruiting structure reduced EML4::ALK protein expression but did not produce the same result against NPM::ALK. This provides a useful example of fusion-context-dependent E3 performance. MDM2 can be considered as an exploratory recruitment option, but it should not be presented as an established ALK PROTAC system without direct supporting degradation data.

Table 3. Structural Design Strategies for ATP-Competitive ALK PROTACs.

Mutation-Directed ALK Degrader Design for Resistance Mutations and Compound Mutants

Target Site: Gatekeeper, Solvent-Front, αC-Helix, and Activation-Loop Mutation Environments

ALK resistance mutations can alter the local structure of the kinase domain and change the recognition profile of ATP-competitive ligands. L1196M is a gatekeeper substitution that changes the steric environment near the ATP-binding pocket. G1202R is a solvent-front mutation that introduces a bulky positively charged side chain at the entrance to the pocket. These changes can interfere with inhibitor positioning and alter the space available for linker attachment.

Other mutations affect additional kinase-domain regions. C1156Y is located near the N-lobe and αC-helix region, while I1171T/N and V1180L can alter local kinase-domain packing and inhibitor recognition. G1269A, D1203N, S1206Y/C, and E1210K introduce further changes around the kinase core and activation-loop region. The exact structural effect varies by substitution and receptor conformation; therefore, the design should be based on the specific mutant structure rather than assuming that all mutations simply enlarge or narrow the ATP pocket.

Compound mutations create an additional challenge because two substitutions on the same ALK molecule can produce combined structural effects. G1202R/L1196M is particularly important because it combines solvent-front and gatekeeper changes. C1156Y/L1198F and L1196M/L1198F provide other examples of compound-mutant environments. These structures require evaluation of both the ALK-binding pose and the orientation of the linker-bearing degrader.

Warhead Selection: Mutation-Covering versus Mutation-Selective ALK Binders

Mutation-directed warhead selection should distinguish broad mutant coverage from selective recognition of a specific mutant. A broad-coverage ligand is useful when the intended degrader must maintain binding across several ALK variants. A mutation-selective ligand may be appropriate when a particular substitution produces a distinct pocket environment that can be exploited through complementary steric, hydrophobic, or polar interactions.

CPD-1224 provides an important example of a mutation-covering design. Its ceritinib-derived ALK-binding component was incorporated into a CRBN-recruiting PROTAC and optimized through pharmacological and physicochemical evaluation. The resulting degrader demonstrated activity against the highly resistant EML4::ALK G1202R/L1196M compound mutant, including degradation in an animal model.

WZH-17-002 represents another mutation-oriented architecture. Its target-binding component, WZH-15-125, was selected because of its ability to recognize ALK resistance-associated forms, including G1202R/L1196M. Connecting this ligand to a CRBN recruiter produced a degrader with a reported DC₅₀ of approximately 25 nM. This example supports selecting the warhead according to mutant recognition first, followed by optimization of the complete degrader.

SIAIS164018 and SIAIS117 provide additional brigatinib-derived precedents for evaluating G1202R-associated ALK. The dEALK1 degrader also demonstrated degradation of multiple ceritinib-resistant EML4::ALK variants. More recently, TRI-611 introduced a different approach by recruiting CRBN through a degron interface on the ALK kinase domain that is distal to the conventional ATP-binding site. This non-orthosteric recognition strategy provides an alternative route when mutations interfere with conventional inhibitor-derived warheads.

• Broad-coverage warheads: prioritize scaffolds with demonstrated binding across wild-type and multiple mutant ALK forms. Evaluate CPD-1224 and WZH-17-002 as important design precedents.
• Mutation-informed warheads: use structural analysis to identify whether a substitution changes local steric volume, polarity, or hydrogen-bonding opportunities.
• Alternative recognition: consider non-orthosteric approaches when mutations within the ATP pocket substantially reduce inhibitor-derived ligand recognition.
• Binding confirmation: compare the parent ligand and linker-bearing intermediate against the same mutant panel before interpreting complete degrader performance.

Linker Design: Preserving Ternary Complex Formation Across Mutant ALK Conformations

A linker that supports degradation of wild-type ALK may not retain the same performance against a mutant receptor. Mutation-induced changes in the kinase pocket can alter the warhead's orientation and the position of its solvent-exposed substituent. Even when the target-binding ligand maintains sufficient affinity, the attached E3 recruiter may be positioned differently relative to the ALK surface.

Mutation-resolved linker optimization should therefore use matched chemical series. The same warhead and E3 recruiter can be connected through several linker lengths and structural types to determine whether the mutation changes the productive ternary-complex geometry. Structural modeling can help identify potential clashes between the recruited E3 ligase and the altered ALK kinase surface, but experimental degradation measurements remain necessary.

Recent polyhedral alkane linker research provides an additional design direction. BL-1 to BL-5 incorporated cubane, homocubane, adamantane, D₃-trihomocubane, and norbornene structures into brigatinib- and lenalidomide-based PROTACs. BL-5, containing a norbornene linker, showed effective ALK degradation and activity in a G1202R mutant model. These results support testing rigid three-dimensional linkers when conventional flexible chains do not provide suitable ternary-complex stability.

• Mutation-specific modeling: compare wild-type and mutant ALK structures to determine whether the warhead exit vector remains accessible.
• Matched linker series: maintain the same target ligand and E3 recruiter while varying linker length and composition.
• Rigid architectures: evaluate cyclic, heterocyclic, and polyhedral linkers when flexibility produces unstable or nonproductive ternary complexes.
• Mutant-resolved degradation: compare DC₅₀, D_max, and degradation kinetics across individual and compound mutants.

E3 Ligase Selection: Matching Recruiter Chemistry to Resistant ALK Contexts

E3 recruitment should be evaluated independently from mutant ALK binding. CRBN has particularly strong support in mutation-directed ALK degradation, including CPD-1224, WZH-17-002, and TRI-611. The advantage of CRBN recruitment is not simply its ligand availability; the complete CRBN-ALK interaction must position the ubiquitination machinery appropriately relative to the mutant protein.

VHL provides a useful alternative comparison, particularly for brigatinib-derived structures such as SIAIS117. However, the different outcomes observed with gilteritinib-based CRBN-, IAP-, and VHL-recruiting designs demonstrate that a recruiter that works for one fusion protein or ligand scaffold may not work equally well for another. IAP recruitment can therefore be evaluated as an additional option, but its performance against each mutant and fusion context must be demonstrated independently.

For resistant ALK programs, the recommended approach is to establish a productive CRBN-based reference design and compare alternative E3 systems using matched target-binding ligands and linkers. This makes it easier to determine whether poor degradation results from mutant recognition, ternary-complex geometry, or E3 recruitment rather than changing several structural variables simultaneously.

Table 4. Structural Design Strategies for Mutation-Directed ALK Degraders.

Fusion-Directed ALK Degrader Design for ALK Fusion Proteins and Neuroblastoma-Associated ALK Forms

Target Site: Fusion-Driven Oligomerization Interfaces and the Retained ALK Kinase Domain

ALK fusion proteins contain a partner-derived region joined to the intracellular portion of ALK. The retained kinase domain provides the most established target-binding surface for small-molecule degrader design. In EML4::ALK, the EML4-derived region contributes oligomerization properties that support constitutive kinase activation. In NPM::ALK, the NPM1 fusion partner also promotes oligomerization and abnormal ALK signaling. Other ALK fusion partners can produce different protein architectures and subcellular distributions.

For most inhibitor-derived PROTACs, the fusion junction itself is not the primary binding site. Instead, the warhead recognizes the conserved ALK kinase domain, while the fusion partner influences the conformation, accessibility, and spatial environment of the target. This distinction is important because an ALK degrader may recognize the same kinase pocket in different fusion proteins but still produce different degradation outcomes due to differences in protein localization, oligomerization, and E3 ligase accessibility.

Neuroblastoma-associated ALK forms require a different structural consideration. Unlike EML4::ALK and NPM::ALK, activating mutations such as F1174L and R1275Q can occur in the full-length transmembrane receptor. These forms retain their extracellular and transmembrane regions as well as the intracellular kinase domain. Therefore, both intracellular kinase-domain-directed degradation and extracellular receptor-directed degradation may be considered, depending on the receptor's cellular distribution.

Warhead Selection: Ligands for EML4-ALK, NPM-ALK, and Other Fusion and Mutant Contexts

A kinase-domain-binding warhead can provide broad recognition across ALK fusion proteins because EML4::ALK and NPM::ALK retain the same principal catalytic region. Ceritinib-derived ligands in TD-004 and MS4078 demonstrated that one inhibitor-binding framework could be used to target both fusion contexts. The later gilteritinib-based study also showed that the same target-binding scaffold could be evaluated against EML4::ALK and NPM::ALK, although its degradation performance depended on the recruited E3 ligase.

Alectinib-derived and brigatinib-derived ligands provide additional options. SIAIS001 and SIAIS091 demonstrated CRBN-associated degradation using an alectinib-derived framework, while SIAIS117 and SIAIS164018 showed that brigatinib-derived structures could be paired with different E3 recruitment systems. AP-1 further demonstrated that an ultrashort-linker architecture could degrade NPM::ALK and EML4::ALK as well as the F1174L ALK mutant.

For neuroblastoma-associated ALK, full-length receptor expression and mutant status should be considered separately. The AP-1 study demonstrated activity against F1174L ALK, while more recent linker-free Pro-BA research also reported degradation of wild-type full-length ALK. However, the reported potency against full-length ALK was lower than against EML4::ALK, illustrating that activity against a fusion protein should not be assumed to translate directly to the intact receptor.

• Shared kinase-domain strategy: prioritize kinase-binding ligands when the intended targets are EML4::ALK, NPM::ALK, or other fusion proteins retaining the ALK catalytic domain.
• Fusion-specific evaluation: compare degradation across different fusion partners rather than assuming identical activity based on kinase-domain sequence alone.
• Full-length ALK: evaluate receptor conformation, membrane distribution, and mutant-specific recognition separately from fusion-protein models.
• Alternative warhead chemistry: consider non-orthosteric or degron-based recognition when conventional kinase-pocket targeting provides insufficient coverage.

Linker Design: Accommodating Fusion Partner-Driven Oligomerization and Subcellular Localization

Fusion partners can influence the spatial organization of the ALK kinase domain and therefore affect how an E3 ligase approaches the target. The oligomerization state of EML4::ALK or NPM::ALK may change the accessibility of the kinase surface and surrounding lysine residues. Consequently, the optimal linker geometry in one fusion model may not be equally productive in another.

The 2024 gilteritinib-based study demonstrated that shorter linkers could improve degradation activity across the tested fusion proteins. However, the different outcomes observed between EML4::ALK and NPM::ALK also showed that linker optimization cannot be separated from E3 selection and fusion context. A linker that supports productive CRBN recruitment may not provide the same orientation with an IAP or VHL recruiter.

For fusion-directed design, the linker should be optimized using a combination of structural modeling and protein-degradation measurements. The target-binding portion should remain anchored within the kinase pocket, while the linker should extend away from the fusion-associated structural environment. A focused series containing flexible, partially rigid, and ultrashort linkers can help identify the most productive geometry without unnecessarily increasing molecular size.

E3 Ligase Selection: E3 Choice for Cytoplasmic Fusion Pools and Membrane-Proximal ALK

E3 selection is particularly important when different fusion proteins exhibit distinct intracellular distributions. CRBN has been used successfully in degrader studies targeting both EML4::ALK and NPM::ALK. VHL recruitment also supported ALK degradation in TD-004, demonstrating that the intracellular E3 machinery can be exploited for fusion-derived ALK proteins.

The gilteritinib-based study provides a useful comparison: its CRBN-recruiting degrader reduced both EML4::ALK and NPM::ALK protein expression, while its IAP-recruiting counterpart showed activity against EML4::ALK but not NPM::ALK. The VHL-based design was ineffective in that particular series. These results emphasize that E3 compatibility is determined by the complete degrader structure and the target protein context rather than by the identity of the E3 ligase alone.

For full-length membrane-associated ALK, conventional intracellular E3 recruitment remains possible when the degrader can cross the cell membrane and bind the intracellular kinase domain. However, extracellular-domain-directed strategies require different degradation routes because conventional intracellular E3 ligases cannot directly access an extracellularly bound ligand. This distinction should guide the selection between intracellular PROTACs and membrane-directed degrader formats.

Table 5. Structural Design Strategies for Fusion-Directed ALK Degraders.

Alternative ALK Degrader Design Using Hydrophobic Tags, Linker-Free Degrons, and Click-Formed Degraders

Target Site: Reusing the ALK Kinase Pocket Without a Conventional E3 Recruitment Arm

Alternative ALK degrader strategies can retain the established kinase-binding region while replacing the conventional E3 ligand-linker architecture with a different degradation signal. Hydrophobic tagging is one example. In this approach, an ALK-binding ligand is connected to a hydrophobic fragment that changes the protein's interaction with cellular quality-control machinery. The resulting hydrophobic surface can promote chaperone recognition and subsequent degradation through the ubiquitin-proteasome system.

Amino-acid-based degrons provide another approach. Rather than connecting an ALK ligand to a conventional small-molecule CRBN or VHL recruiter, a degradation signal is directly attached to the target-binding ligand. The degron can recruit an endogenous substrate-recognition system and facilitate ubiquitination. Therefore, linker-free PROTACs do not necessarily eliminate E3 recruitment; they replace the conventional E3-binding ligand with a compact degradation signal.

These approaches should be distinguished from molecular glue degraders. TRI-611, for example, promotes ALK-CRBN proximity through a defined molecular recognition interface rather than using a conventional two-ligand PROTAC architecture. Hydrophobic tags, amino-acid degrons, and molecular glues therefore provide different ways of connecting ALK recognition to cellular protein-degradation machinery.

Ligand and Tag Selection: Hydrophobic Tags, Amino-Acid Degrons, and Bioorthogonal Precursors

Hydrophobic tag selection should consider both the hydrophobicity of the tag and the binding properties of the attached ALK ligand. HyT-9 used an alectinib-derived ligand connected to a norbornene hydrophobic tag. The compound promoted ALK degradation through Hsp70-associated mechanisms and the ubiquitin-proteasome system. Subsequent research introduced adamantane-based tags, with H7 identified as an effective ALK degrader. Other work developed norbornene-based J26 and bornane-based J21, further expanding the available hydrophobic fragments.

Amino-acid degrons provide a different structural design space. Pro-BA, Gly-BA, and Arg-BA were developed by directly connecting amino-acid degradation signals to a brigatinib-derived ALK ligand. Pro-BA uses an N-terminal proline signal recognized by GID4, a substrate receptor associated with the CTLH E3 ligase complex. The resulting target-E3 interaction promotes ALK ubiquitination and proteasomal degradation. The Gly- and Arg-based structures demonstrated that different amino-acid signals can produce distinct degradation behavior.

Further development of amino-acid-based miniPROTACs has introduced ornithine (Orn) and 2,4-diaminobutyric acid (Dab) degrons. Orn-BA and Dab-BA directly connect these unnatural amino-acid-based degradation signals to a brigatinib-derived ALK ligand. These compact structures provide another alternative to conventional CRBN- or VHL-binding components.

Bioorthogonal precursors provide a potential route for assembling degrader components through selective chemical reactions. A solvent-exposed ALK ligand substituent could be functionalized with an azide, alkyne, or another compatible reaction handle, while the complementary E3 recruiter carries the corresponding partner group. Click chemistry can then be used to construct the final bifunctional structure. However, an ALK-specific click-assembled degrader was not identified in the research examples reviewed here. This approach should therefore be treated as a synthetic design option rather than an established ALK degradation mechanism.

Linker Design: Rigid Bioisosteres, Self-Assembling Spacers, and Complete Linker Removal

Hydrophobic-tag degraders still require an appropriate connection between the ALK-binding ligand and the hydrophobic fragment. HyT-9 and H7 demonstrate the use of customized linkers to adjust the distance and orientation of the hydrophobic group relative to the target-bound ligand. Linker length can influence both ALK recognition and the presentation of the hydrophobic tag to chaperone-associated machinery.

Rigid three-dimensional linkers offer an alternative to conventional flexible chains. The BL-1 to BL-5 series incorporated different polyhedral structures into brigatinib- and lenalidomide-based ALK PROTACs. Their structural diversity provides a useful way to examine whether conformational restriction improves ternary-complex stability. BL-5, which contains a norbornene linker, showed effective ALK degradation in the reported research. These results support the use of three-dimensional linker structures when conventional PEG or alkyl chains do not provide suitable molecular geometry.

Linker-free PROTACs take a more direct approach. Pro-BA and other amino-acid degron conjugates eliminate the conventional spacer by directly connecting the degradation signal to the ALK-binding ligand. In the reported Pro-BA study, the linker-free molecule showed stronger target binding and more effective GID4-associated ternary-complex formation than its PEG-linker-containing comparator. This demonstrates that adding a linker is not always beneficial.

For self-assembling or click-compatible designs, the spacer should be considered as part of the final assembled molecule. Bioorthogonal handles can simplify the preparation of matched degrader libraries, but the resulting product still requires an appropriate spatial connection between the target ligand and the recruitment element. Complete linker removal should instead be considered a separate design strategy based on direct degron-ligand conjugation.

Degradation Route Selection: Proteasomal, Chaperone-Associated, and Click-Assembly Pathways

Different alternative ALK degrader formats engage distinct cellular degradation mechanisms. Hydrophobic tags such as HyT-9, H7, J26, and J21 can promote chaperone-associated protein destabilization. Hsp70 has been implicated in these ALK degradation processes, while proteasome inhibition experiments support involvement of the ubiquitin-proteasome system. Notably, J26 retained ALK degradation activity in a model with reduced CRBN expression, demonstrating that hydrophobic tagging can provide an alternative to conventional CRBN-dependent recruitment.

Amino-acid degrons operate through endogenous substrate-recognition systems. Pro-BA recruits GID4, which recognizes an N-terminal proline signal and facilitates the interaction between the degrader and EML4::ALK. The resulting ubiquitination supports proteasomal degradation. Other amino-acid degrons can recruit different recognition systems, so their performance should be assessed individually rather than assuming that all amino-acid signals use the same E3 complex.

Glutathione-responsive Y-PROTACs provide another structural option. The reported Y5-3 architecture uses a disulfide-containing design to release an ALK degrader component together with a second functional component after reduction. This demonstrates how a cleavable connection can introduce stimulus-dependent changes in degrader activity. However, the ALK degradation mechanism must still be evaluated separately from the behavior of the additional component.

Click assembly is different from these degradation pathways. It is primarily a method of constructing the active degrader rather than a cellular degradation mechanism by itself. Once assembled, the final molecule must still recruit the appropriate E3 ligase or another degradation-associated system and demonstrate target-dependent protein depletion.

Table 6. Alternative ALK Degrader Formats and Their Structural Design Features.

Membrane-Directed ALK Degrader Design for Extracellular-Domain Targeting

Target Site: Surface-Exposed MAM, LDLa, and Glycine-Rich Regions of Full-Length ALK

Full-length ALK provides a distinct target architecture because its extracellular domain is exposed outside the cell and connected to the intracellular kinase domain through a transmembrane segment. The extracellular region contains two MAM domains, an LDLa domain, and a glycine-rich region close to the membrane. These structural elements provide potential recognition surfaces for extracellular-domain-directed degraders.

The two MAM domains and the intervening LDLa region offer potential starting points for antibody or peptide binder development. The glycine-rich region is closer to the membrane and may provide a different accessibility profile. However, glycosylation, local protein flexibility, and the limited structural information available for the complete ALK extracellular domain can influence binder accessibility. Therefore, epitope selection should be supported by domain mapping and experimental binding assessment rather than sequence position alone.

It is also important to distinguish extracellular-domain targeting from conventional kinase-domain degradation. A cell-permeable PROTAC can bind the intracellular kinase domain of full-length ALK without recognizing its extracellular region. Linker-free Pro-BA research demonstrated degradation of full-length wild-type ALK, although the reported DC₅₀ was approximately 2.1 μM, substantially higher than its reported potency against EML4::ALK. This finding demonstrates that intact membrane-associated ALK can be affected by intracellular degrader designs, but it does not establish an extracellular-domain-directed degrader.

Binder Selection: Antibody Fragments, Peptides, and Small-Molecule Extracellular Ligands

Antibody-based binders provide a practical starting point for extracellular ALK recognition because they can engage larger and more accessible protein surfaces than conventional small molecules. Full-length antibodies, antibody fragments, and engineered binding proteins can be evaluated against the MAM and LDLa regions. Peptide binders may provide smaller molecular formats, while small-molecule extracellular ligands could be considered when a defined recognition pocket is identified.

Previous ALK receptor studies have demonstrated that antibody binding can influence receptor internalization and degradation. Agonistic antibodies were reported to induce ALK internalization, ubiquitination, and lysosomal degradation, with recruitment of the Cbl ubiquitin ligase. In contrast, antagonist antibodies promoted receptor internalization followed by recycling to the plasma membrane. These findings provide a useful biological precedent for selecting binders according to their effects on receptor trafficking.

For degrader development, the selected binder should therefore be evaluated for both affinity and trafficking behavior. A binder that strongly recognizes the extracellular domain but directs ALK toward recycling may not provide the same degradation outcome as one that promotes sustained internalization and lysosomal delivery.

• Antibody fragments: evaluate Fab, scFv, or other compact formats when a defined extracellular epitope is available.
• Peptide binders: consider when the selected MAM or LDLa surface provides a reproducible recognition interface.
• Small-molecule ligands: investigate only when structural evidence supports an accessible extracellular binding pocket.
• Trafficking behavior: distinguish agonistic internalization and lysosomal delivery from antagonist-associated recycling.

Linker and Format Design: Valency, Cleavable Spacers, and Binder Orientation

Membrane-directed degraders require different linker considerations from intracellular PROTACs. The binder must first engage the extracellular portion of ALK while presenting a second functional component in an orientation that promotes receptor internalization or recruitment of a suitable trafficking system. Linker length, flexibility, valency, and attachment position can all affect this process.

Bivalent binders may increase receptor clustering and influence internalization, but excessive crosslinking can also alter receptor signaling or produce nonproductive aggregates. Monovalent formats may provide better control over receptor engagement but may require an additional internalization or lysosomal-targeting component. These alternatives should be compared using matched binder and linker designs.

Cleavable spacers can be considered when the degrader requires intracellular release of a targeting component after receptor internalization. However, cleavage should occur at an appropriate stage of trafficking and should not compromise the initial binding or internalization process. The preferred architecture will depend on the ALK epitope, binder orientation, and selected degradation route.

Degradation Route Selection: Lysosome-Targeting Receptors, Transmembrane E3 Ligases, and Recycling Routes

Extracellular-domain-directed ALK degradation requires a route that can transfer the membrane-associated target into an appropriate intracellular degradation compartment. Lysosome-targeting approaches can connect an extracellular ALK binder to a receptor that undergoes endocytosis and delivers the complex toward lysosomes. For example, a lysosome-targeting chimera architecture could combine an ALK-binding component with a ligand that recognizes the cation-independent mannose-6-phosphate receptor (CI-M6PR).

Another possible approach is to recruit a membrane-associated E3 ligase. An engineered antibody-based format could connect an ALK extracellular binder to a transmembrane E3 system, such as RNF43, to promote receptor ubiquitination and subsequent internalization. Such designs require careful consideration of membrane topology because the extracellular binding domain and intracellular ubiquitination machinery occupy different cellular compartments.

Receptor recycling is another important consideration. If ALK is internalized but returned to the plasma membrane, the overall reduction in receptor abundance may remain limited. Therefore, trafficking studies should distinguish internalization from productive lysosomal delivery and sustained receptor depletion.

At present, these extracellular-domain-directed architectures should be considered exploratory ALK degrader strategies rather than established ALK-specific LYTAC or antibody-based degrader examples. The reported antibody-induced ALK internalization and lysosomal degradation provide a biological starting point, but an engineered extracellular-domain-targeting degrader requires independent validation of binder recognition, trafficking, and degradation.

Table 7. Structural Design Strategies for Membrane-Directed ALK Degraders.

How BOC Sciences Supports ALK Degrader Development

ALK degrader development requires coordinated optimization of target recognition, linker architecture, E3 recruitment, and degradation mechanism. BOC Sciences supports these activities through research materials, custom molecular design, synthesis, and experimental evaluation. Whether the project focuses on conventional ALK PROTACs, resistance-associated mutants, fusion proteins, hydrophobic tags, or membrane-directed degradation, the development strategy can be adapted to the structural characteristics of the selected ALK form.

ALK Target Form and Mutation Feasibility Assessment

• Identify the intended ALK form, including full-length ALK, EML4::ALK, NPM::ALK, and selected point or compound mutants.
• Evaluate the accessibility of the kinase domain, extracellular region, and potential degrader recognition surfaces.
• Compare wild-type and mutant structures to identify possible changes in warhead recognition and linker exit vectors.
• Assess protein turnover, accessible ubiquitination surfaces, and E3 ligase availability before selecting a degrader architecture.

ALK Warhead and Binder Design Support

• Evaluate ceritinib-, alectinib-, brigatinib-, and other ALK-binding scaffolds for target-specific degrader development.
• Identify solvent-exposed attachment positions and design linker-bearing ligand analogues.
• Support mutation-covering and mutation-selective warhead design for resistant ALK forms.
• Explore antibody, peptide, and extracellular binder options for full-length ALK receptor targeting.

Linker and E3 Ligase System Design with Custom Degrader Synthesis

• Develop matched linker libraries covering PEG, alkyl, rigid heterocyclic, polyhedral, and cleavable architectures.
• Compare CRBN, VHL, IAP, and other suitable recruitment systems according to the intended ALK target form.
• Support hydrophobic tag conjugation, amino-acid degron attachment, and bioorthogonal assembly strategies.
• Prepare custom ALK degrader candidates, intermediates, and related building blocks with purification and analytical characterization.

Degradation Mechanism and Developability Evaluation

• Evaluate ALK binding, ternary-complex formation, and E3 recruitment to identify structural limitations.
• Measure target ubiquitination and degradation depth using suitable mechanism-focused assays.
• Compare DC₅₀, D_max, degradation kinetics, and concentration-dependent activity across ALK variants.
• Assess solubility, cellular permeability, stability, and exposure-related properties of optimized degrader candidates.

Explore featured products that can expand your research options and accelerate your next discovery.

Access end-to-end service solutions that help bring efficiency, flexibility, and expertise to your research pipeline.

News

• Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology
• Degrader Building Blocks for Targeted Protein Degradation
• Recent Progress of PROTACs Targeting Non-enzymatic Functional Proteins
• Discovery of Molecular Glue Degraders

Technical Information

• Proteolysis-Targeting Chimeras (PROTAC)
• Targeted Protein Degradation: The Next Frontier in Drug Discovery
• Overview of 12 Targeted Protein Degradation Technologies
• Peptide and Small Molecule Based PROTACs Technology